Ganitumab
Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IGF-1R |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| Chemical and physical data | |
| Formula | C6472H10028N1728O2020S42 |
| Molar mass | 145712.01 g·mol−1 |
 N Y (what is this?) (verify) | |
Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.[3][4]
References
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American MedicaAssociation.
- Martínez P, Sales Fidalgo PA, Felip E (October 2014). "Ganitumab for the treatment of small-cell lung cancer". Expert Opinion on Investigational Drugs. 23 (10): 1423–32. doi:10.1517/13543784.2014.951434. PMID 25189625. S2CID 7318164.
- "Amgen Pulls Cancer Drug". 10 Aug 2012. Archived from the original on 2013-07-23.
- "Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial". 8 Aug 2012. Archived from the original on 2012-08-10.
Growth factor receptor modulators | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Angiopoietin |
| ||||||||||
| CNTF |
| ||||||||||
| EGF (ErbB) |
| ||||||||||
| FGF |
| ||||||||||
| HGF (c-Met) |
| ||||||||||
| IGF |
| ||||||||||
| LNGF (p75NTR) |
| ||||||||||
| PDGF |
| ||||||||||
| RET (GFL) |
| ||||||||||
| SCF (c-Kit) | |||||||||||
| TGFβ |
| ||||||||||
| Trk |
| ||||||||||
| VEGF |
| ||||||||||
| Others |
| ||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.